Latest Market Entry News

Firebird Metals has advanced its manganese-rich battery materials with a patented energy-saving kiln and precursor cathode outperforming Chinese benchmarks, while planning an Australian Demonstration Plant to break into Western markets.

Osteopore Limited has inked a three-year exclusive distribution agreement with MontsMed to introduce its advanced orthopaedic trauma reconstruction products into Hong Kong, positioning itself strategically within the Greater Bay Area.

Ionic Rare Earths has secured a listing on the U.S. OTCQB Venture Market, enhancing access for American investors to its rare earth and magnet recycling ventures. This move aligns the company with North American critical minerals priorities and broadens its global investor base.

RooLife Group Ltd has reported a remarkable doubling of its coffee and food sales in China, surpassing A$2.1 million in December 2025 and signaling strong momentum in its data-driven e-commerce strategy.

Ovanti Limited has completed a $1 million capital raise through a discounted share placement to accelerate its buy now, pay later business expansion in the United States.

Neurizon Therapeutics has secured trademark protection for its NEURIZON® brand across major pharmaceutical markets, reinforcing its intellectual property strategy as it advances its lead drug candidate NUZ-001.

Orthocell Limited has reported a record $3.2 million revenue for the December 2025 quarter, marking its seventh consecutive quarter of growth, fuelled by expanding sales of its nerve repair product Remplir in the US and other international markets.

Iondrive Limited appoints Lewis Utting as CEO to spearhead the transition from technology development to commercial execution of its IONSolv™ platform, while refreshing its board with new expertise.

SRJ Technologies’ UAE subsidiary has landed a US$879k contract to manage a major controls upgrade for a Middle Eastern National Oil Company, marking a key step in its regional expansion.

Neuren Pharmaceuticals’ partner Acadia projects DAYBUE sales to reach around US$700 million by 2028, driven by US market expansion and international approvals. The launch of a new formulation and ongoing clinical trials in Japan underpin this optimistic outlook.

Proteomics International Laboratories has appointed David Morris as CEO and Managing Director, marking a strategic shift towards commercialising its Promarker® diagnostic technology. Morris brings extensive global healthcare leadership experience to lead the company’s next growth phase.

ECS Botanics reports a $218k positive operating cash flow in Q2 FY26, driven by strong B2C growth and new product launches. The company also secured $1.95 million in funding to fuel European expansion and product development.